赛托生物(300583.SZ)：甲泼尼龙收到化学原料药上市申请批准通知书

Core Viewpoint - Saito Biopharmaceuticals (300583.SZ) has received approval from the National Medical Products Administration for the marketing application of Methylprednisolone, a corticosteroid used in emergency treatment for critical illnesses and various other medical conditions [1] Group 1: Company Developments - Saito Biopharmaceuticals' subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has been granted a marketing approval notice for Methylprednisolone [1] - Methylprednisolone is classified as a medium-acting, non-halogenated corticosteroid [1] Group 2: Product Applications - The drug is indicated for emergency treatment in critical illnesses and can also be used for endocrine disorders, rheumatic diseases, collagen diseases, skin diseases, allergic reactions, ophthalmic diseases, gastrointestinal diseases, blood diseases, leukemia, shock, cerebral edema, multiple neuritis, myelitis, and to prevent vomiting caused by cancer chemotherapy [1]